Introduction
Anticoagulant management represents an ever increasing workload for clinicians and the laboratory service. It is important that all aspects of clinical and laboratory tests are carefully monitored through current quality assurance schemes and clinical audit. Changes in the indications for anticoagulation have resulted in a progressive increase in patients requiring lifelong oral anticoagulant therapy. This increase is mainly a consequence of patients with atrial fibrillation and underlying cardiac problems requiring anticoagulation. As treatment is lifelong the effect on the number of visits to the outpatient clinic is cumulative.
In 
Audit of anticoagulant prophylaxis
The audit of anticoagulant prophylaxis is a difficult undertaking, requiring considerable time to access information from different sources. There may be, however, considerable resource and financial benefit in the long term. The sample population can be obtained by identifying patients with ICD codes for DVT and PE through the hospital patient administration system. This should include cases with other primary diagnoses at admission, developing thromboembolic complications while inpatients. To identify patients developing thrombotic events after discharge is more difficult. Information on readmissions within three months including high risk postoperative cases can be audited.
Of 105 patients with DVT/PE audited recently, 30 had undergone a surgical procedure within three months of admission, four of whom died. Five of the 30 patients were given prophylactic anticoagulant treatment with low dose standard subcutaneous heparin for five to eight days. The thromboembolic event was diagnosed in seven of the 30 patients during the postoperative inpatient stay. The 23 patients who developed a thromboembolic event after discharge following surgery were readmitted within five to 52 days (mean 24 days), with a total additional hospital inpatient stay amounting to 243 days.
In the present climate of restricted finances, a pragmatic approach to prophylactic anticoagulation may be cost-effective. The outcome of this audit was to reassess the thrombosis risk score sheet, where patients with four or more risk factors were given prophylactic heparin, and to extend the indications to other orthopaedic surgical procedures. In these clinical groups low molecular weight heparin therapy is now routinely used in preference to standard low dose heparin.
The quality of anticoagulant service A patient's concept of quality of service can be monitored using standard hospital quality criteria. Anticoagulant clinics suffer by virtue of the number of patients attending and the frequency of recall. A patient's view of quality of service may focus on the size of the hospital car park, and the time taken for review. Therefore, efforts to decentralise large clinics and provide local near patient testing and dosing are worthy of evaluation. Recently, small oral anticoagulant analysers have become available for near patient testing,9 with capillary blood sample analysis, simple handling and immediate availability of results from one drop of blood. However, with near patient testing there is still an important need for hospitals to provide and ensure access to appropriate quality assurance schemes, with guidelines to local services-for example, general practices un- Audit of medical records from these patients showed that reversal of over-anticoagulation using the BCSH guidelines was not complied with for 61 % of cases, and in seven cases this was potentially hazardous. Concurrent infection, disseminated intravascular coagulation, other drug interactions, and the presence of liver disease were identified as major risk factors in this group of over-anticoagulated patients. Furthermore, the mean patient age of the over-anticoagulated patients was significantly higher at 70 years than that of the overall group at 57 years. Several reports'2 13 have now clearly documented that clinicians need to be particularly careful when initiating warfarin therapy in elderly patients. Hospital policies for anticoagulation need to incorporate reduced loading doses for patients over the age of 70 years starting warfarin therapy.
While the establishment of audit programmes may involve an initial increase in workload, the long term benefits may result in better inpatient and outpatient control, using less qualified staff. For example, the use of routine inpatient treatment charts is beneficial to all grades of staff involved in anticoagulant monitoring. Furthermore, the decentralisation of anticoagulant practice with well monitored quality assurance is likely to be of benefit to both clinicians and the increasing numbers of patients on lifelong anticoagulant therapy. 
